Bifogade filer
Kurs
+6,54%
Kurs
+6,54%
Open
1,12
High
1,32
Low
1,05
Close
1,11
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
7,48 MNOK
Likviditet
7,48 MNOK
Rel. mcap
1,02%
Antal aktier
6 205 537
Likviditet under dagen för detta pressmeddelande
Kalender
Tid* | ||
2025-04-24 | N/A | Årsstämma |
2025-02-26 | 07:00 | Bokslutskommuniké 2024 |
2025-01-06 | N/A | Extra Bolagsstämma 2025 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2024-04-11 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2023-04-26 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-08-31 | - | Kvartalsrapport 2022-Q2 |
2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2022-04-28 | - | Årsstämma |
2022-03-01 | - | Bokslutskommuniké 2021 |
2021-11-18 | - | 15-10 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-04-28 | - | Årsstämma |
2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2021-03-22 | - | Extra Bolagsstämma 2021 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-10-21 | - | Extra Bolagsstämma 2020 |
2020-08-27 | - | Kvartalsrapport 2020-Q2 |
2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2020-06-10 | - | Årsstämma |
2020-05-26 | - | Kvartalsrapport 2020-Q1 |
2020-04-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | Kvartalsrapport 2019-Q1 |
2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2019-04-25 | - | Årsstämma |
2019-02-18 | - | Extra Bolagsstämma 2019 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2018-05-30 | - | Årsstämma |
2018-05-30 | - | Kvartalsrapport 2018-Q1 |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-12-20 | - | Extra Bolagsstämma 2017 |
2017-11-22 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2017-05-24 | - | Årsstämma |
2017-05-24 | - | Kvartalsrapport 2017-Q1 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-23 | - | Kvartalsrapport 2016-Q3 |
2016-10-12 | - | Extra Bolagsstämma 2016 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-31 | - | Kapitalmarknadsdag 2016 |
2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
2016-05-19 | - | Årsstämma |
2016-05-19 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-17 | - | Kapitalmarknadsdag 2015 |
2015-10-21 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-27 | - | Kvartalsrapport 2015-Q1 |
2015-03-09 | - | Årsstämma |
2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2024-06-06 08:00:05
6.6.2024 08:00:01 CEST | Thor Medical ASA | Non-regulatory press releases
Oslo, Norway, 6 June 2024: Thor Medical and Steenkampskraal Holdings Limited in
South Africa have signed a Memorandum of Understanding for feedstock supply and
technology cooperation. The ambition is to enter into a long-term partnership
agreement for supply of feedstock as part of the Thor Medical's strategy of
developing multiple feedstock suppliers.
The Steenkampskraal Monazite Mine in the Western Cape is considered to have
among the highest concentration of rare earth elements and thorium globally. The
mine's abundant resources of natural thorium are sufficient to meet the global
demand for medical isotopes from its decay for the foreseeable future. The plan
is to leverage Thor Medical's expertise to efficiently produce valuable
alpha-emitters for use in next generation cancer treatment from feedstock from
Steenkampskraal's mineral resources.
"The cooperation with Steenkampskraal can support Thor Medical's ambitions for
the planned industrial-scale production to meet the growing demand for medical
isotopes globally. We look forward to developing partnership agreements with
Steenkampskraal as we build our network of suppliers," says Alf Bjørseth, CEO of
Thor Medical.
The Steenkampskraal Monazite Mine is a fully licensed to operate mining project
and is compliant with all necessary regulatory requirements from, inter alia the
Department of Mineral Resources and Energy, the National Nuclear Regulator, and
the Department of Water and Sanitation. The mine has already commenced with
refurbishment and the start-up of the construction is targeted by end of 2024.
Production of thorium is targeted by end of 2025.
About Thor Medical
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
About Steenkampskraal
Steenkampskraal Monazite Mine aims to become a leading producer of rare earth
elements (REEs) and thorium, specifically focusing on monazite extraction.
Located in South Africa, the mine boasts significant deposits of monazite, a
mineral rich in REEs essential for various industries such as electronics,
renewable energy, and defense. Steenkampskraal's business strategy emphasizes
sustainable mining practices, technological innovation, and strategic
partnerships to ensure long-term success.
CONTACTS
* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3180/4614/Download%20announcement
%20as%20PDF.pdf